The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin‐α
- 7 March 2016
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 36 (9) , 1295-1303
Abstract
Background & Aims: Rifaximin‐α reduces the risk of recurrence of overt hepatic encephalopathy. However, there remain concerns regarding the financial cost of the drug. We aimed to study the impact of treatment with rifaximin‐α on healthcare resource utilisation using data from seven UK liver treatment centres.Methods: All seven centres agreed a standardised data set and data characterising clinical, demographic and emergency hospital admissions were collected retrospectively for the time periods 3, 6 and 12 months before and following initiation of rifaximin‐α. Admission rates and hospital length of stay before and during therapy were compared. Costs of admissions and drug acquisition were estimated using published sources. Multivariate analyses were carried out to assess the relative impact of various factors on hospital length of stay.Results: Data were available from 326 patients. Following the commencement of rifaximin, the total hospital length of stay reduced by an estimated 31–53%, equating to a reduction in inpatient costs of between £4858 and £6607 per year. Taking into account drug costs of £3379 for 1‐year treatment with rifaximin‐α, there was an estimated annual mean saving of £1480–£3228 per patient.Conclusions: Initiation of treatment with rifaximin‐α was associated with a marked reduction in the number of hospital admissions and hospital length of stay. These data suggest that treatment of patients with rifaximin‐α for hepatic encephalopathy was generally cost saving.Keywords
Funding Information
- National Institute for Health Research
- Newcastle upon Tyne Hospitals NHS Foundation Trust
- Newcastle University
This publication has 21 references indexed in Scilit:
- A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With CirrhosisClinical Gastroenterology and Hepatology, 2016
- Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver DiseasesJournal of Hepatology, 2014
- Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled studyAlimentary Pharmacology & Therapeutics, 2011
- Clinical Course of Alcoholic Liver Cirrhosis: A Danish Population-Based Cohort StudyHepatology, 2010
- Rifaximin Treatment in Hepatic EncephalopathyNew England Journal of Medicine, 2010
- Spectrum of neurocognitive impairment in cirrhosisHepatology, 2009
- The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammationCellular and Molecular Life Sciences, 2005
- Influence of Hepatic Encephalopathy on Health-Related Quality of Life in Patients with CirrhosisDigestive Diseases and Sciences, 2003
- Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998Hepatology, 2002
- Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patientsJournal of Hepatology, 2001